EXCLUSIVE: Vivani Medical Tells Benzinga 'Clinical development of Vivani's exenatide implant in overweight and obese patients as part of the Company's NPM-115 program remains on track to commence in the fourth quarter of 2024'
Portfolio Pulse from Benzinga Newsdesk
Vivani Medical announced that the clinical development of its exenatide implant for overweight and obese patients is on track to begin in Q4 2024 as part of its NPM-115 program.
September 04, 2024 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivani Medical is progressing with its NPM-115 program, planning to start clinical development of its exenatide implant for obesity in Q4 2024.
The announcement of the clinical development timeline for Vivani's exenatide implant is a positive signal for investors, indicating progress in their product pipeline. This could lead to increased investor confidence and potential stock price appreciation as the development progresses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100